logo

Omeros Corp. (OMER)



Trade OMER now with
  Date
  Headline
1/4/2018 7:42:45 AM Wedbush Reiterates Omeros Corp. (OMER) At Outperform With $47 Price Target
1/3/2018 7:03:29 AM Omeros Reaches Deal With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy
12/12/2017 7:03:14 AM Omeros Corp. Announces FDA Approval Of OMIDRIA For Use In Pediatric Patients
11/28/2017 3:32:58 PM Wedbush Is Cutting Omeros Corp. (OMER) 2018 Estimate To -0.24 From 0.26
11/28/2017 3:32:34 PM Wedbush Is Lowering Omeros Corp. (OMER) 4Q18 Estimate To 0.02 From 0.18
11/28/2017 3:32:14 PM Wedbush Is Cutting Omeros Corp. (OMER) 3Q18 Estimate To -0.05 From 0.14
11/28/2017 3:31:58 PM Wedbush Is Cutting Omeros Corp. (OMER) 2Q18 Estimate To -0.09 From 0.03
11/28/2017 3:31:32 PM Wedbush Is Lowering Omeros Corp. (OMER) 1Q18 Estimate To -0.13 From -0.09
11/28/2017 3:31:10 PM Wedbush Is Increasing Omeros Corp. (OMER) 2017 Estimate To -0.95 From -1.09
11/28/2017 3:30:39 PM Wedbush Is Raising Omeros Corp. (OMER) 4Q17 Estimate To -0.13 From -0.17
11/28/2017 3:28:57 PM Wedbush Is Increasing Omeros Corp. (OMER) 2018 Rev. Estimate To 168.9 M From 121.5 M
11/28/2017 3:28:27 PM Wedbush Is Cutting Omeros Corp. (OMER) 4Q18 Rev. Estimate To 36.1 M From 53.7 M
11/28/2017 3:27:58 PM Wedbush Is Lowering Omeros Corp. (OMER) 3Q18 Rev. Estimate To 31.5 M From 46.0 M
11/28/2017 3:27:36 PM Wedbush Is Lowering Omeros Corp. (OMER) 2Q18 Rev. Estimate To 28.6 M From 38.2 M
11/28/2017 3:27:18 PM Wedbush Is Cutting Omeros Corp. (OMER) 1Q18 Rev. Estimate To 25.3 M From 31.0 M
11/28/2017 3:26:43 PM Wedbush Is Raising Omeros Corp. (OMER) 2017 Rev. Estimate To 75.5 M From 75.0 M
11/28/2017 3:26:27 PM Wedbush Is Lowering Omeros Corp. (OMER) 4Q17 Rev. Estimate To 24.4 M From 25.5 M
11/28/2017 3:23:59 PM Wedbush Reiterates Omeros Corp. (OMER) At Outperform With $47 Price Target